Allogeneic haematopoietic stem cell transplantation (HSCT) represents the first choice of treatment or an important therapeutic option for numerous diseases. Several stem cell sources, such as bone marrow, mobilised peripheral blood stem cells and umbilical cord blood, are suitable for HSCT in clinical practice. However, this procedure is strongly related to availability of a histocompatible donor. In order to increase the probability of finding a histocompatible donor, national and international registries have been developed. Voluntary donation of bone marrow or peripheral blood stem cells for HSCT, both in the related or unrelated setting, is a well-established procedure with an invaluable ethical significance. Even if both procedures are safe, they are not risk free; therefore, the greatest attention has to be paid to the donor and to the donation process through a careful monitoring protocol for donor safety.
Allogeneic haematopoietic stem cell transplant (HSCT) has evolved from an experimental therapy to an elective treatment for many haematological and non-haematological diseases. HSCT is strongly related to the availability of a histocompatible donor -around 25 % among family members. The establishment of national registries of haematopoietic stem cell donors and cord blood units joined worldwide enables finding a suitable donor in patients without a human leukocyte antigen (HLA)-matched sibling.
Today, more than 18 million haematopoietic stem cell donors and cord blood units from 65 registries and 47 cord blood banks are available to provide life-saving stem cells to patients. 1 The last European blood and bone marrow transplant (EBMT) survey reported 26,859 first transplants, of which 40 % were allogeneic, performed in 615 centres during 2008. 2 In Italy during 2009, the Gruppo Italiano trapianto di midollo osseo (GITMO) registered 1,474 allogeneic transplants. 3 Over the past decade, a major shift has occurred from bone marrow (BM) to cytokine-mobilised peripheral blood stem cell (PBSC) collection as the main procedure for obtaining allogeneic haematopoietic stem cells. 4 Haematopoietic stem cells are present in bone marrow and represent the 0.1 % of circulating cells in the peripheral blood. This percentage may increase to 5 % after mobilisation.
Influence of Stem Cell Source on Transplant Outcome
There are phenotypic and biological differences between BM and PBSC.
Due to a higher number of CD34+ cells, a shorter time to engraftment both in nucleated cells and in platelets is observed with PBSC, 5 however, the higher number of T-lymphocytes infused with PBSC appears to increase the incidence of chronic graft-versus-host disease (GVHD). in death or is life-threatening, requires in-patient hospitalisation, considerably prolongs existing hospitalisation, or results in persistent or significant disability/incapacity must be reported.
The WMDA has developed recommendations about the eligibility criteria and evaluation of donor health with a view to ensuring donor safety during the entire donation process.
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Family and Voluntary Unrelated Donation
Although unrelated donors benefit from standardised care guidelines established by national and international donor registries and associated organisations, 10, 11 no specific guidelines are available for related donors. 12 Another important factor that distinguishes related from unrelated donors is the relationship between donor and recipient. 13 This relationship may push the donor to hide some important medical information in order to be considered eligible for the donation. at the site of aspiration and anaemia. 17 The donor may require pain killers for a short time after the procedure and some time off work. The fatal and serious adverse events reported are fortunately rare.
Type of Anaesthesia
BM harvest may be performed under GA or RA. Although both methods are generally considered to be safe and are commonly used, there are only a few reports that compare their safety and efficacy among stem cell donors. [18] [19] [20] In a recent retrospective study of 281 BM donations (207 GA, 74 RA), no significant difference was noted regarding numbers of adverse events during and after the procedure. This observation strongly suggests that there is no 'anaesthesia of choice' and that the choice depends on the donor or the anaesthetist's preference. Moreover, when a growth factor is administered in a healthy donor, the highest attention has to be paid to possible late effects and in particular to malignancies. 23 Several studies have been performed with the aim of evaluating the long-term incidence of leukaemia in stem cell donors after G-CSF administration. In particular, Bennett et al. 24 have described two cases of acute myeloid leukaemia in related donors after mobilisation with rhG-CSF. More information on this topic is available from registry studies: in a National Marrow Donor Program (NMDP) analysis performed on 2,408 unrelated PBSC donors from 1999 to 2004, with a median follow-up of 44 months, the incidence of cancer in the donor cohort did not significantly differ from that of the control population. In particular, no case of myelodysplasia or myeloid leukaemia was observed in donors receiving rhG-CSF. 25 In another study from the German Bone Marrow Donor Centre (DKMS) on 3,928 unrelated PBSC donations, malignancies occurred in 12 donors; only the incidence of Hodgkin's lymphoma (two cases) differed significantly from that observed in an age-adjusted population. 26 Larger prospective studies are needed to evaluate the real incidence of haematological diseases in healthy donors.
Use of Biosimilars in Peripheral Blood Stem Cell Mobilisation
The increasing use of stem cell mobilisation and collection from the same advice should also be considered for autologous stem cell mobilisation. 28 In this setting, a preliminary report on patients affected by multiple myeloma and lymphoproliferative diseases comparing standard G-CSF versus biosimilar (ratiograstim) showed similar results in terms of days for collection and CD34+ yield. 29 The WMDA has adopted the same policy as the EBMT and states that any new product for mobilisation should not be used until safety data are available. The main limits of this study were due to limited reports of donor experiences, short follow-up and inappropriate and heterogeneous psychological morbidity assessment among the trials. 38 The previously reported EBMT analysis 14 40 The occurrence of malignancies has not to be directly correlated with the donation and as reported by others, does not significantly differ from that of the control population. Moreover, particular attention must be paid in the recruitment of related donors to their potential older age and to hidden morbidity. n
